Merola Joseph F, Ogdie Alexis, Gottlieb Alice B, Stein Gold Linda, Flower Andrea, Jardon Shauna, Klyachkin Yuri, Lebwohl Mark
Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
University of Pennsylvania, Philadelphia, PA, USA.
Dermatol Ther (Heidelb). 2023 Jun;13(6):1329-1346. doi: 10.1007/s13555-023-00929-9. Epub 2023 May 15.
The Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) survey study was conducted globally in 2020 to understand how disease perceptions, including disease severity, treatment goals, and quality of life (QoL), have evolved recently, especially for mild-to-moderate psoriatic disease. Here, key findings from the UPLIFT survey based on respondents located in the US are presented. Leveraging results from the UPLIFT survey could lead to more effective interactions between patients and physicians and greater patient satisfaction.
UPLIFT was a multinational web-based survey of dermatologists, rheumatologists, and patients who self-reported a healthcare provider diagnosis of psoriasis (PsO) and/or psoriatic arthritis (PsA) conducted from March 2, 2020, to June 3, 2020.
US respondents included 1006 patients (26.4% of global population; PsO only, n = 535; PsA only, n = 72; PsO and PsA, n = 399) and 216 physicians (dermatologists, n = 115; rheumatologists, n = 101). Most patients (66.4%) reported a body surface area (BSA; assessed by number of palms) of ≤ 3; of these, 56.2% rated their disease as moderate or severe. Most patients with PsO felt they were somewhat (40.1%) or very (49.3%) closely aligned with their dermatologists regarding treatment goals. Alternately, most patients with PsA felt that they were not too closely (32.1%) or not at all (59.3%) aligned with their rheumatologists. Most patients reported either a moderate (PsO, 35.5%; PsA, 31.8%) or strong (PsO, 47.7%; PsA, 53.9%) need for better treatments. Across BSA subgroups, most patients (60.8% to 86.1%) had a Dermatology Life Quality Index score ≥ 6, indicating at least a moderately impacted QoL.
Despite more treatment options, management of psoriatic disease remains suboptimal, with many patients reporting moderate-to-severe disease and impaired QoL, even with limited skin involvement. Results further suggest an unmet need for alignment between patients and physicians in the US to optimize the management of PsO and PsA.
“利用见解促进银屑病治疗理解”（UPLIFT）调查研究于2020年在全球范围内开展，旨在了解疾病认知，包括疾病严重程度、治疗目标和生活质量（QoL）最近是如何演变的，尤其是对于轻至中度银屑病。在此，呈现基于美国受访者的UPLIFT调查的主要结果。利用UPLIFT调查结果可能会使患者与医生之间的互动更有效，并提高患者满意度。
UPLIFT是一项基于网络的跨国调查，调查对象为皮肤科医生、风湿病学家以及自我报告经医疗服务提供者诊断患有银屑病（PsO）和/或银屑病关节炎（PsA）的患者，调查于2020年3月2日至2020年6月3日进行。
美国受访者包括1006名患者（占全球总人数的26.4%；仅患PsO的患者，n = 535；仅患PsA的患者，n = 72；同时患PsO和PsA的患者，n = 399）以及216名医生（皮肤科医生，n = 115；风湿病学家，n = 101）。大多数患者（66.4%）报告体表面积（BSA；通过手掌数量评估）≤3；其中，56.2%将其疾病评为中度或重度。大多数PsO患者认为他们在治疗目标方面与皮肤科医生有些（40.1%）或非常（49.3%）一致。相比之下，大多数PsA患者认为他们与风湿病学家不太（32.1%）或完全不（59.3%）一致。大多数患者报告对更好治疗有中度（PsO为35.5%；PsA为31.8%）或强烈（PsO为47.7%；PsA为53.9%）需求。在BSA亚组中，大多数患者（60.8%至86.1%）的皮肤病生活质量指数得分≥6，表明生活质量至少受到中度影响。
尽管有更多治疗选择，但银屑病的管理仍不理想，许多患者报告患有中度至重度疾病且生活质量受损，即使皮肤受累有限。结果进一步表明，美国患者与医生之间在优化PsO和PsA管理方面存在未满足的需求。
